Integrin-FAK Inhibitors: FAK
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Integrin-FAK Inhibitors: FAK
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT04625270: RAMP 201 | II | Avutometinib, Defactinib | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | The combination of avutometinib with defactinib yields encouraging response rates with a well tolerated safety profile in women with heavily pretreated recurrent LGSOC regardless of KRAS status and with prior MEK inhibitor treatment Avu+Def vs Avu: ORR: 45 vs 10% KRAS MUT: KRAS WT: abs Jun 2023 and poster, abs Mar 2024 |
| NCT01778803 | I | Defactinib, Paclitaxel | A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer | Defactinib + weekly paclitaxel is well tolerated and showed promising activity ORR: 18.2% abs May 2014 and poster |
| NCT03875820; FRAME | I | Defactinib, Avutometinib | FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours | VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with LGSOC including those who have been previously treated with a MEK inhibitor ORR: 46% abs Apr 2021 and poster, abs Sep 2021 |